Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amylyx Pharmaceuticals, Inc. - Common Stock
(NQ:
AMLX
)
2.230
+0.010 (+0.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amylyx Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration
August 12, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
August 05, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Analyst Ratings For Amylyx Pharma
July 12, 2024
Via
Benzinga
Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome
August 02, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
July 12, 2024
Via
Benzinga
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
July 10, 2024
Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor antagonist, ready for Phase 3 trial for post-bariatric hypoglycemia and...
Via
Benzinga
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
July 10, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
6 Analysts Assess Amylyx Pharma: What You Need To Know
June 24, 2024
Via
Benzinga
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide
July 09, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Breaking Down Amylyx Pharma: 9 Analysts Share Their Views
May 10, 2024
Via
Benzinga
AMLX Stock Earnings: Amylyx Pharma Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
AMLX stock results show that Amylyx Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Unveiling 6 Analyst Insights On Amylyx Pharma
April 08, 2024
Via
Benzinga
Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
May 09, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
May 08, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder
April 10, 2024
Amylyx's AMX0035 data in treating Wolfram syndrome, with interim data indicating positive effects on diabetes progression, visual decline, and overall disease burden. Safety profile consistent.
Via
Benzinga
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
April 10, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
AMLX DEADLINE TOMORROW: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
April 08, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
AMLX DEADLINE TOMORROW: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
April 08, 2024
WHY: NEW YORK, NY - (NewMediaWire) - April 08, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) between November...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)
April 08, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
AMLX DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action – AMLX
April 08, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
April 08, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
AMLX IMPORTANT DEADLINE: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
April 07, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
AMLX IMPORTANT DEADLINE: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
April 07, 2024
WHY: NEW YORK, NY - (NewMediaWire) - April 07, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) between November...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
AMLX DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
April 06, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
AMLX DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
April 06, 2024
WHY: NEW YORK, NY - (NewMediaWire) - April 06, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) between November...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
AMLX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
April 05, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
AMLX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX
April 05, 2024
WHY: NEW YORK, NY - (NewMediaWire) - April 05, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) between November...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.